NASDAQ : GELS
Gelteq Limited — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Australia
Last price 0.506 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.66M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.26M |
| Enterprise Value | 8.66M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 17, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 11.18M |
| Shares Outstanding | 11.18M |
| Shares Change (YoY) | +21.92% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 29.64% |
| Owned by Institutions (%) | 2.55% |
| Float | 5.15M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.42 |
| Forward PS | n/a |
| PB Ratio | 0.58 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 28.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.09 |
| Quick Ratio | 0.07 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.93 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -42.93% |
| Return on Assets (ROA) | -17.61% |
| Return on Invested Capital (ROIC) | -18.97% |
| Return on Capital Employed (ROCE) | -44.72% |
| Weighted Average Cost of Capital (WACC) | 14.30% |
| Revenue Per Employee | $39,338 |
| Profits Per Employee | -$590,582 |
| Employee Count | 8 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 3.63 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.36 |
| 52-Week Price Change | -59.16% |
| 50-Day Moving Average | 0.56 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 48.26 |
| Average Volume (20 Days) | 85,968 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 314,643 |
| Short Previous Month | 520,734 |
| Short % of Shares Out | 2.81% |
| Short % of Float | 6.11% |
| Short Ratio (days to cover) | 0.20 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 314,701 |
| Gross Profit | 237,728 |
| Operating Income | -4.25M |
| Pretax Income | -4.72M |
| Net Income | -4.72M |
| EBITDA | -3.43M |
| EBIT | -4.25M |
| Loss Per Share | -$0.47 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6,236 |
| Total Debt | 3.41M |
| Net Cash | -3.40M |
| Net Cash Per Share | -$0.30 |
| Equity (Book Value) | 9.47M |
| Book Value Per Share | 0.85 |
| Working Capital | -3.56M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.12M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 869,641 |
| Net Borrowing | -175,335 |
| Free Cash Flow | -2.12M |
| FCF Per Share | -$0.19 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.54% |
| Operating Margin | -1,351.12% |
| Pretax Margin | -1,501.31% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -21.92% |
| Shareholder Yield | -21.92% |
| Earnings Yield | -99.74% |
| FCF Yield | -38.59% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.54 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |